Der var investor relations møtereferat ute:
"2. When will APL-1702 be approved? What have been done in the promotion work?
Prepare?
Reply:
The company has launched a series of commercial preparations, mainly including: promoting the publication of clinical data; maintaining active communication with clinical experts and supporting relevant societies to carry out guideline consensus updates; carrying out disease burden research and policy research on accessibility and payment burden; supporting the fertility-friendly Blue Book project to carry out policy calls. Call for the construction of fertility-friendly; accelerate the formation of commercialization teams and carry out omni-channel commercialization layout with public hospitals as the core; communicate with doctors about the photodynamic non-invasive therapy mechanism and the latest clinical data; improve the public’s awareness of pre-cervical lesions through public welfare publicity; optimize the product commercialization supply chain to ensure that After the product is approved
Benefit the patient for a while. The listing application of APL-1702 was obtained in May 2024.
After the acceptance of the State Drug Administration, the company listed the review and approval of its listing as the top priority, and focused on alloliging resources to promote it. Up to now, the Drug Review Center of the State Drug Administration has launched the second round of technical review. The company will speed up its listing review and approval in order to obtain listing approval as soon as possible."
Så det blir epler og vannmeloner å sammenligne de to.
